Share on LinkedInShare on LinkedIn

ARTICLE · 02 OCTOBER 2014

Lessons From GlaxoSmithKline’s Record $492 Million Bribery Fine In China

Pharmaceutical giant GlaxoSmithKline plc announced that its Chinese subsidiary had been found guilty of bribing health officials in the country.

CanadaInternational Law

On September 19, 2014, pharmaceutical giant GlaxoSmithKline plc (GSK) announced that its Chinese subsidiary had been found guilty of bribing health officials in the country and was forced to swallow a 3 billion yuan ($492 million CDN) penalty, the largest corporate fine in China's history. Five of the company's managers were also given suspended prison sentences of two to four years' probation after the one-day trial in Hunan Province. GSK has announced that it is not seeking to appeal.

This bulletin will review what led to GSK's bitter medicine in China's courts and what lessons this example holds for other foreign companies operating in the country or trying to combat their own corruption risks more broadly.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from